Gene Signal Will Expand Antisense Ophthalmic Studies With New Funds
This article was originally published in The Pink Sheet Daily
Executive Summary
A topical antisense product, aganirsen, from Switzerland’s Gene Signal is to be evaluated in neovascular glaucoma, age-related macular degeneration and psoriasis following the completion of a Phase III study in corneal graft rejection.
You may also be interested in...
Gene Signal Novel Corneal Neovascularization Product Still On Track Despite Primary Endpoint Miss
Although visual acuity is no longer thought to be a useful primary endpoint for drugs targeting corneal neovascularization, Gene Signal will keep developing its first-in-class antisense product in that and other ophthalmic indications.
Genzyme/Isis Gear Up For Long-awaited Kynamro Launch
Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.
EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).